Prostate cancer patients undergoing radical prostatectomy increased by double digits while those undergoing brachytherapy decreased.
A questionnaire-based study revealed significant side effects that are not commonly discussed.
Radiotherapy given within 6 months of radical prostatectomy reduces cancer-specific mortality in men with highly aggressive disease.
High rates of preserved sexual function with combination beam plus brachytherapy.
Utilization rates jumped by double digits across prostate cancer risk groups from 2004 to 2011.
Men with male pattern baldness may face a higher risk of aggressive prostate cancer.
This benefit is not seen in patients who undergo radical prostatectomy, according to an updated meta-analysis.
Black prostate cancer patients more likely to develop aggressive disease earlier than white patients.
Low-dose aspirin decreased the likelihood of acute genitourinary toxicity in prostate cancer by 27%.
Enzalutamide and abiraterone may not benefit men with metastatic castration-resistant prostate cancer who have AR-V7 in circulating tumor cells.
However, they are more likely to die from causes other than prostate cancer than men with normal metabolic levels.
The drug is now also approved for use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.
Study finds a 15-year cancer-specific survival rate of 94%; hormone therapy for more than 6 months decreases all-cause survival.
Detection of AR-V7 in circulating tumor cells linked to enzalutamide and abiraterone resistance.
New study highlights the importance of digital rectal examinations in PCa patients with normal-range PSA at diagnosis.
Findings seen in economically disadvantaged men with newly diagnosed prostate cancer.
Studies show integrated program effective for depression in patients with cancer.